| Document |
Document Title |
|
WO/2024/026556A1 |
The present disclosure relates to modified coronavirus S protein and virus-like particles (VLPs) comprising modified coronavirus S protein. The present invention also relates to methods of increasing the purity, and/or stability of coron...
|
|
WO/2024/027758A1 |
The present invention provides a universal immune effector cell, and in particular a universal CAR-T cell (IRU-CAR-T), a preparation method therefor, and use thereof. The universal CAR-T cell introduces a CAR and a mutated CnA or CnB fra...
|
|
WO/2024/030601A1 |
The present disclosure provides an engineered dermis comprising one or more layers of human dermal fibroblast compositions as well as scaffolds and methods of the same. The disclosure also provides compositions comprising one or more int...
|
|
WO/2024/029561A1 |
Provided is a tumor-bearing immune nonhuman animal that enables suppression of the onset of graft-versus-host disease (GVHD) and engraftment of T cells and/or B cells. Human peripheral blood monocytes are transplanted into a tumor-bear...
|
|
WO/2024/028486A1 |
The present invention relates to an in vitro method for obtaining clinical-grade CD8+ CD45RClow/- regulatory T (Treg) cells, to a pharmaceutical composition comprising said population of Treg cells and uses thereof.
|
|
WO/2024/029529A1 |
The present disclosure relates to: a method for producing a plant or an isolated plant cell that produces collagen; a nucleic acid construct to be used for the method; and a method for producing collagen protein using the aforesaid plant...
|
|
WO/2024/027532A1 |
Disclosed herein is a method for thawing an ovum or embryo. The method comprises the following steps: respectively loading a preheated oil, a diluent, a cleaning liquid and a culture solution into different containers; taking out a carri...
|
|
WO/2024/029535A1 |
The present invention provides a polypeptide that specifically recognizes a structurally abnormal protein caused by misfolding, etc. in mammals, and a detection agent and a reduction agent for a structurally abnormal protein with the use...
|
|
WO/2024/029617A1 |
The present invention provides a method that is for producing atrial cardiac muscle cells from premature cardiac muscle cells and that comprises (a) a step for culturing a cell population including premature cardiac muscle cells in the p...
|
|
WO/2024/030864A1 |
The present disclosure relates to novel procedures for cryoprotection of tissues for imaging procedures such as correlative light and electron microscopy (CLEM) and immunogold electron microscopy (iEM) and fluorescence imaging. The proce...
|
|
WO/2024/029629A1 |
The present invention addresses the problem of providing a porous scaffold for cell culture that does not deteriorate even subjected to a sterilization treatment such as autoclaving and enables culture of various cells, and a production ...
|
|
WO/2024/030969A1 |
A system for active circulation of bioink in inkjet bioprinting, comprises a bioink reservoir, an inlet connected to a pump, an outlet from the pump to the bioink reservoir, wherein the pump circulates bioink from the inlet to the outlet.
|
|
WO/2024/029630A1 |
The present disclosure provides a cyclic peptide derivative, a method for producing the same, and a composition. The present disclosure pertains to a compound for neural cell activity regulation. More specifically, the compound of the pr...
|
|
WO/2024/030662A1 |
The disclosure provides host cells engineered to express non-naturally occurring polyketide synthases that produce b-keto-d-lactones (BKDLs); methods of generating such host cells, and methods of producing BKDLs employing the host cells.
|
|
WO/2024/030758A1 |
The present invention provides compositions comprising chimeric receptors, including chimeric costimulatory receptors (CCRs), and/or chemokine receptors, methods for preparing CCRs and/or chemokine receptors, and therapeutic populations ...
|
|
WO/2024/030344A1 |
Methods, systems and computer-readable media for identifying optimized cell media formulations capable of promoting the expression of a biomolecule of interest are presented, which may include applying mixing algorithms, culturing cells,...
|
|
WO/2024/030569A1 |
A novel human T-cell acute lymphoblastic leukemia (T-ALL) cell line called INB16 (ATCC Deposit no. PTA-125809) induces memory like function on natural killer cells upon contact therewith, which memory like natural killer cells have demon...
|
|
WO/2024/030959A1 |
Provided are methods for differentiating cardiomyocytes from pluripotent stem cells, e.g., induced pluripotent stem cells, that involves dissociation and re-aggregation of cell aggregates, as well as to populations of cardiomyocytes, agg...
|
|
WO/2024/026566A1 |
A microfluidic device is provided for culturing cell spheroids or organoids and therapeutics screening, the microfluidic device comprising a shell and an at least one sector, the shell comprising a multiplicity of segments, each segment ...
|
|
WO/2024/026676A1 |
A preparation system and preparation method for VitroOrganoSpheres with core-shell structure, and a total system. The preparation system comprises a microfluidic chip. A cell fluid flow channel of a shell structure, a cell fluid flow cha...
|
|
WO/2024/027223A1 |
The present invention provides an in vivo and in vitro editing preparation method for CAR-MΦ targeting tumor stem cells, and a use thereof. The invention provides a chimeric antigen receptor-macrophage (CAR-MΦ) and a nano-carrier based...
|
|
WO/2024/024671A1 |
The purpose of the present invention is to provide a material that can promote the proliferation of animal cells through addition to a serum-reduced culture medium. It was found that a plant protein material having a specified molecula...
|
|
WO/2024/024708A1 |
The present invention addresses the problem of providing a novel composition for cartilage repair including cells that have characteristics suitable for cartilage repair, and a method for producing same. With a focus on umbilical cord ...
|
|
WO/2024/025950A1 |
Disclosed herein is an "in silico perturbation" Variational Autoencoder (VAE)-based deep learning framework. Such a framework can predict alterations in gene expression profiles caused by perturbations of transcription factor (TF) expres...
|
|
WO/2024/024720A1 |
Provided are a method, an agent, etc. for enhancing the stability of a medium and enhancing the productivity of a recombinant protein. More specifically, provided are: a medium containing N-acetylcysteine and L-cysteine; a method for cul...
|
|
WO/2024/026313A1 |
Provided are methods of producing avian embryonic stem cells. In certain embodiments, the methods comprise culturing epiblast cells obtained from a stage IX-XI avian embryo in a cell culture medium present in a feeder-free cell culture c...
|
|
WO/2024/024337A1 |
Provided are: a device for purifying and concentrating a liquid that contains a minute useful substance, the device being capable of producing a liquid that contains a minute useful substance at high purity and high concentration (a puri...
|
|
WO/2024/024929A1 |
The present invention relates to a method for producing three-dimensional muscle tissue, the method including the following steps (A) and (B): (A) a step for supplying a myoblast-containing hydrogel to a culture container, the culture co...
|
|
WO/2024/023524A1 |
Provided herein are methods and compositions for growing cells. The cells may comprise engineered nucleic acids. The methods provided herein may comprise growing the cells comprising the engineered nucleic acids, or a progeny or populati...
|
|
WO/2024/024955A1 |
Provided is a method for producing a vagus-nerve-like parasympathetic nerve cell, the method comprising (a) a step for inducing the differentiation of a pluripotent stem cell into a parasympathetic nerve cell, and (b1) a step for introdu...
|
|
WO/2024/026445A1 |
Provided herein are engineered immune cells and populations thereof for administration to subjects to treat cancer (e.g., solid tumors or liquid tumors) and other conditions. The cells are engineered to functionally express a reduced lev...
|
|
WO/2024/024932A1 |
It was found that administering a composition containing cancer cells that express damage-associated molecular patterns (DAMPs) to a subject using a needleless syringe causes the cancer cells in the composition to be damaged by shear for...
|
|
WO/2023/246838A9 |
Provided is a disease model and use thereof. In particular, provided is an engineered human cell with a mutated APP gene, a cellular model derived from the engineered human cell and use thereof.
|
|
WO/2024/024895A1 |
The present invention provides a treatment agent for NK2 Homeobox 1 (NKX2-1)-negative lung adenocarcinomas that includes a Porcupine inhibitor as an active ingredient, an NKX2-1-negative lung adenocarcinoma organoid, and a screening meth...
|
|
WO/2023/196220A9 |
Described herein are compositions comprising zinc fingers and methods of use thereof for the treatment of nucleotide repeat expansion disorders such as Ewing Sarcoma.
|
|
WO/2024/024561A1 |
This method for producing keratinocytes includes a separation step that is repeated multiple times, in which step trypsinization is performed on a cell population including keratinocytes induced from pluripotent stem cells, to separate k...
|
|
WO/2024/022008A1 |
The present invention relates to the field of biomedicine, and in particular, provided is an anti-Siglec-15 monoclonal antibody or an antigen-binding fragment thereof. The anti-Siglec-15 monoclonal antibody comprises a heavy chain variab...
|
|
WO/2024/024742A1 |
The present invention provides a method for producing oocytes or follicles, or a reconstituted ovary containing oocytes or follicles, the method comprising a step for culturing a reconstituted ovary of a primate under a suspension cultur...
|
|
WO/2024/026232A1 |
Methods and compositions are provided for driving expression of a coding sequence that has been integrated within the genome of a cell. A donor polynucleotide is integrated within the genome so that a non-functional promoter is located d...
|
|
WO/2024/024336A1 |
Provided are: a purifying and concentrating device for a liquid comprising a minute useful substance, the device being capable of producing a liquid (purified concentrated liquid of a minute useful substance) comprising a minute useful s...
|
|
WO/2024/022462A1 |
The present invention provides an anti-ILT4 single-domain antibody and an antigen-binding fragment thereof. The present invention further provides a method for treating or preventing a disease in a subject using same, and a method for pr...
|
|
WO/2024/022495A1 |
This disclosure provides anti-MerTK antibodies, variants thereof and humanized versions. The newly disclosed antibodies exhibited high affinity to the MerTK protein and can be used to treat cancers, in particular solid tumors.
|
|
WO/2024/020909A1 |
Disclosed herein is directed to a lactate oxidase variant that exhibits reduced affinity to lactate as compared to a wild-type lactate oxidase. The lactate oxidase variant has one or more amino acid substitutions occurring at positions 9...
|
|
WO/2024/021839A1 |
A humanized monoclonal antibody or an antigen-binding fragment thereof that has improved stability and specifically binds to human ACE2, a product related thereto, and a preparation method therefor and the use thereof. The anti-human ACE...
|
|
WO/2024/024646A1 |
The present invention provides an expression vector carrying a gene encoding LHFPL6 protein and a gene encoding TM7SF3 protein. The present invention also provides a vector set comprising an expression vector carrying a gene encoding LHF...
|
|
WO/2024/022513A1 |
Provided herein is a method for preparing a universal chimeric antigen receptor T (UCAR-T) cell, comprising: knocking out genes such as TRAC, B2M, CD5 and CD7 in a T cell, and transfecting the T cell to enable the expression of a chimeri...
|
|
WO/2024/024806A1 |
This phenolic compound production method is a method for producing a compound represented by formula (2) from a compound represented by formula (1), and comprises a step for bringing an enzyme into contact with the compound represented b...
|
|
WO/2024/023245A1 |
Disclosed herein are cell culture methods, methods of producing a cell for use in adoptive cell therapy, methods of transducing an immune cell with a viral vector, and uses of products derived from the methods e.g. medical uses and thera...
|
|
WO/2024/025825A1 |
The disclosure relates to bioreactor systems and related methods for electrically stimulating cells. For example, this disclosure relates to bioreactors that include an enclosure configured to block externally originating electromagnetic...
|
|
WO/2024/026407A1 |
Multispecific constructs, e.g., bispecific constructs, which comprise an anti-B cell binding arm that specifically binds to a B-cell-specific cell surface marker such as CD20, CD19, CD21, CD24, or CD38, and a second binding arm that spec...
|
